Royalty Pharma plc (NASDAQ:RPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Royalty Pharma plc (NASDAQ:RPRX) have been given a consensus rating of “Moderate Buy” by the five brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $43.00.

Several research firms have recently weighed in on RPRX. Bank of America dropped their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. UBS Group downgraded Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price on the stock. in a research report on Monday, June 3rd. Finally, StockNews.com cut Royalty Pharma from a “buy” rating to a “hold” rating in a report on Friday, May 10th.

Institutional Investors Weigh In On Royalty Pharma

Several institutional investors and hedge funds have recently modified their holdings of the company. Fidelis Capital Partners LLC acquired a new position in Royalty Pharma in the 1st quarter valued at about $46,000. GAMMA Investing LLC increased its stake in Royalty Pharma by 172.5% during the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,037 shares during the period. Allworth Financial LP lifted its holdings in Royalty Pharma by 76.7% during the 4th quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 731 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Royalty Pharma by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 802 shares during the period. Finally, Lindbrook Capital LLC grew its stake in shares of Royalty Pharma by 485.2% in the fourth quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 1,999 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $25.88 on Wednesday. Royalty Pharma has a fifty-two week low of $25.83 and a fifty-two week high of $31.66. The firm has a market capitalization of $15.46 billion, a P/E ratio of 19.31, a price-to-earnings-growth ratio of 3.44 and a beta of 0.46. The stock’s fifty day moving average is $27.29 and its two-hundred day moving average is $28.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 12.52 and a current ratio of 12.52.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.02. Royalty Pharma had a net margin of 35.70% and a return on equity of 22.94%. The firm had revenue of $568.00 million for the quarter, compared to analysts’ expectations of $671.45 million. During the same quarter in the previous year, the company posted $1.60 EPS. On average, research analysts anticipate that Royalty Pharma will post 4.03 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 17th were given a dividend of $0.21 per share. The ex-dividend date was Thursday, May 16th. This represents a $0.84 annualized dividend and a dividend yield of 3.25%. Royalty Pharma’s dividend payout ratio is currently 62.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.